CapsoVision Q2 revenue $3.3M (+17% YoY); IPO closes raising $23.4M

CapsoVision, Inc

2025-Q2 EPS reported -$4.49 revenue$6,098,000

Revenue $3.3M, up 17% YoY, driven by higher CapsoCam Plus capsule sales.
Gross profit $1.8M (55% margin) vs. $1.6M (56%) in Q2 2024.
Operating expenses $6.5M, down $0.4M from prior year due to reduced clinical trial costs.
Closed IPO on July 3, 2025, net proceeds of $23.4M; cash was $1.1M at June 30.
Filed 510(k) for CapsoCam Colon in June 2025; AI module addition targeted for FDA approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.